Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Overview of attention for article published in Journal of Clinical Oncology, October 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 6 news outlets
twitter: 24 X users

guideline: 3 clinical guideline sources

Readers on

mendeley: 89 Mendeley

So far, Altmetric has seen 6 news stories from 6 outlets.

Novel Agents Reshape Sequencing Across Different Lymphoma Populations

Cancer Network, 11 Sep 2026

At the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, “Meet-the-Professor” (MTP) Session XIV brought together 3…

Novel Agents Reshape Sequencing Across Different Lymphoma Populations

UBM Medica, 11 Sep 2026

Immunochemotherapy, bispecifics, and next-generation BTK inhibitors dominated discussion of ENKTL, MZL, and Waldenström…

New Advances in Waldenström Macroglobulinemia

OncLive, 27 Dec 2024

NHL stock.adobe.com Waldenström Macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma characterized by the malignant…

Ibrutinib Improves Long-Term Outcomes in Waldenstrom’s Macroglobulinemia

Cancer Therapy Advisor, 29 Oct 2021

Adding ibrutinib to rituximab improves long-term outcomes in patients with Waldenstrom’s macroglobulinemia (WM), according to…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.